非侵襲性がん診断の技術と世界市場

非侵襲性癌診断技術の世界市場は、2025年の1,199億ドルから成長し、2030年末までに1,652億ドルに達すると予測されており、2025年から2030年の予測期間における年平均成長率（CAGR）は6.6%に達するとBCC Research では予測しています。

レポートの内容

•  71のデータ表と63の追加表
•  非侵襲性癌診断および技術の世界市場に関する詳細な分析
•  2022年から2024年、2025年の過去の収益（売上データ）と2030年までのCAGR予測を含む、世界市場の動向分析
•  技術、癌の種類、エンドユーザー、地域別の市場シェア分析を伴う、世界市場の現在の市場規模と収益見通しの推定
•  世界市場のダイナミクス、機会と阻害要因、技術進歩、規制と見通し、マクロ経済要因の影響に関する事実と数値
•  ポーターの5フォースモデルおよびグローバルサプライチェーン分析から得られた洞察
•  次世代の新規非侵襲性癌分子診断プラットフォーム、早期癌検出の現状の方法と将来展望、癌の診断と治療のための新たなバイオマーカー技術のレビュー
•  特定されたすべての市場セグメントにおける、現在の製品、その適応症と入手可能性、および意図された臨床評価出願
•  主要な取得済みおよび公開済み特許を特集した特許レビュー
•  企業の市場シェアとランキング、製品マッピング、戦略的イニシアチブ、M&A活動、ベンチャー資金調達の見通しを含む業界構造の分析
•  消費者の意識、主要企業のESGリスク評価と実践に重点を置いた、サステナビリティ動向とESGの発展の概要
•  F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Koninklijke Philips N.V.、Labcorp Holdings Inc.、Abbottなどの世界有数の企業のプロファイル

Report Highlights

The global market for noninvasive cancer diagnostic technologies is expected to grow from $119.9 billion in 2025 and is projected to reach $165.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.6% during the forecast period of 2025 to 2030.

Report Includes

• 71 data tables and 63 additional tables
• In-depth analysis of the global market for noninvasive cancer diagnostics and technologies
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by technology, cancer type, end user and region
• Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations and prospects, and the impact of macroeconomic factors
• Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
• Review of next-generation novel noninvasive cancer molecular diagnostics platforms, current methods and future perspectives on early-stage cancer detection, and emerging biomarker technologies for diagnosis and treatment of cancer
• Evaluation of the current products, their indications and availability for all the market segments identified, and intended clinical applications
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Profiles of the leading global companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Labcorp Holdings Inc., and Abbott

Report Scope

The report provides an overview of noninvasive cancer diagnostics technologies and global markets, with a detailed analysis of current market trends. It presents global revenue ($ Million) for the base year 2024, estimated data for 2025, and forecast data for 2026 through 2030. It also includes detailed insights into revenues, forecasts, product indications, and market segmentation. The market is segmented by cancer type, technologies, and end user. Regional coverage encompasses North America, Europe, the Asia-Pacific, and South Africa, with detailed analyses of the Middle East and Africa (MEA), including major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India.

This report provides a detailed overview of noninvasive cancer diagnostic products currently available in the market. It also examines cancer incidence and mortality statistics to provide context for market demand, outlines key challenges limiting the widespread adoption of these technologies, and highlights recent innovations shaping the next generation of diagnostic tools. It provides an in-depth overview of industry dynamics, including opportunities, constraints, and the competitive environment, highlighting both international leaders and smaller regional players active in the market.

The report offers a competitive landscape and includes information on major suppliers and manufacturers, describing their core products and strategic focus areas. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio, and recent developments in major companies.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of the Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Diagnostic Imaging Technologies
Advanced Noninvasive Approaches
Conventional Cancer Screening, Diagnostic Assays and Tests
Porter’s Five Forces Analysis
Competitive Rivalry (High)
Potential for New Entrant (Moderate to High)
Threat of Substitutes (Moderate)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Hospitals, Diagnostic Labs, Payers, and Patients) (High)
Macroeconomic Factors Analysis
Rising Disease Burden and Growing Demand for Diagnostics
Healthcare Spending and Payer Dynamics
Macroeconomic Growth and Funding Environment
Technological Advances
Impact of U.S. Tariffs
Chapter 3 Market Dynamics
Overview
Market Drivers
Increasing Prevalence of Cancer
Growing Adoption of Liquid Biopsy Technologies
Shift Toward Early and Preventive Diagnosis
Rising Healthcare Expenditure and R&D Funding
Market Restraints
High Cost of Advanced Diagnostic Technologies
Low Awareness in Developing Regions
Market Opportunities
AI-Enabled Diagnostics and Digital Pathology
Emerging Markets with Underserved Screening Populations
Market Challenges
Shortage of Radiologists
False-Positive and False-Negative Results
Chapter 4 Regulatory Landscape
U.S. Approval Process
EU Approval Process
Asia-Pacific Approval Process
Japan
China
Australia
India
Chapter 5 Emerging Technologiesand Developments
Key Takeaways
Multi-Cancer Early Detection (MCED) Tests
Radiomics Technology
Urine-Based Molecular Tests
Breath-Based Diagnostics (Volatile Organic Compounds)
Multi-Omics Diagnostic Platforms
Patent Analysis
Key Findings
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Market Analysis, by Cancer Type
Key Takeaways
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Stomach Cancer
Liver Cancer
Esophageal Cancer
Bladder Cancer
All Other Cancers
Market Analysis, by Technology Type
Key Takeaways
Diagnostic Imaging Technologies
Advanced Noninvasive Approaches
Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests
Market Analysis, by End User
Key Takeaways
Hospitals
Academic Institutes
Cancer Institutes
Diagnostic Centers
Government and Private Research Institutes
Pharmaceutical Companies
Contract Research Organizations
Geographic Breakdown
Market Analysis, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Key Takeaways
Leading Companies in Global Noninvasive Cancer Diagnostics Market
Key Developments and Strategies
Partnerships and Collaborations
Acquisitions
Key Strategic Activities and Developments
Product Launches and Regulatory Approvals
Chapter 8 Sustainability in Global Noninvasive Cancer Diagnostics Market: An ESG Perspective
Introduction to ESG
Major Manufacturers: ESG Efforts
Concluding Remarks from BCC Research
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBOTT
BD
BIO-RAD LABORATORIES INC.
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
GUARDANT HEALTH INC.
HOLOGIC INC.
ILLUMINA INC.
KONINKLIJKE PHILIPS N.V.
LABCORP
LEICA BIOSYSTEMS NUSSLOCH GMBH
QIAGEN
REVVITY
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
Few Emerging Startups/Market Disruptors

List of Tables

Summary Table : Global Market for Noninvasive Cancer Diagnostics, by Region, Through 2030
Table 1 : Types of Liquid Biopsy and Their Clinical Applications, 2024
Table 2 : Diagnostic Imaging Technologies in Noninvasive Cancer Diagnostics
Table 3 : Advanced Technologies in Noninvasive Cancer Diagnostics
Table 4 : Conventional Technologies in Noninvasive Cancer Diagnostics
Table 5 : Porter’s Five Forces Analysis: Rating Scale
Table 6 : Estimated Cancer Incidence, Age (0-85+), 2022–2045
Table 7 : Estimated Cancer Incidence in Males in the U.S., by Cancer Site, 2025
Table 8 : Estimated Cancer Incidence in Females in the U.S., by Cancer Site, 2025
Table 9 : Some FDA/CE-IVD Approved Liquid Biopsy Tests
Table 10 : NCI Funding Across Cancer Research Areas, 2023
Table 11 : Selected Published Patents for Noninvasive Cancer Diagnostics Technologies, October 2025
Table 12 : Global Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 13 : Global Market for Noninvasive Breast Cancer Diagnostics, by Region, Through 2030
Table 14 : Global Market for Noninvasive Lung Cancer Diagnostics, by Region, Through 2030
Table 15 : Global Market for Noninvasive Colorectal Cancer Diagnostics, by Region,Through 2030
Table 16 : Global Market for Noninvasive Prostate Cancer Diagnostics, by Region, Through 2030
Table 17 : Global Market for Noninvasive Cervical Cancer Diagnostics, by Region, Through 2030
Table 18 : Global Market for Noninvasive Stomach Cancer Diagnostics, by Region, Through 2030
Table 19 : Global Market for Noninvasive Liver Cancer Diagnostics, by Region, Through 2030
Table 20 : Global Market for Noninvasive Esophageal Cancer Diagnostics, by Region, Through 2030
Table 21 : Global Market for Noninvasive Bladder Cancer Diagnostics, by Region, Through 2030
Table 22 : Global Market for All Other Noninvasive Cancer Diagnostics, by Region, Through 2030
Table 23 : Global Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 24 : Global Market for Noninvasive Cancer Diagnostic Imaging Technologies,by Region, Through 2030
Table 25 : Global Market for Noninvasive Cancer Diagnostic Imaging Technologies, by Type, Through 2030
Table 26 : Global Market for Advanced Noninvasive Approaches of Cancer Diagnostics, by Region, Through 2030
Table 27 : Global Market for Advanced Noninvasive Approaches of Cancer Diagnostics, by Type, Through 2030
Table 28 : Global Market for Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests, by Region, Through 2030
Table 29 : Global Market for Conventional Noninvasive Cancer Screening, Diagnostic Assays and Tests, by Type, Through 2030
Table 30 : Global Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 31 : Global Market for Noninvasive Cancer Diagnostics in Hospitals, by Region, Through 2030
Table 32 : Global Market for Noninvasive Cancer Diagnostics in Academic Institutes, by Region, Through 2030
Table 33 : Global Market for Noninvasive Cancer Diagnostics in Cancer Institutes, by Region, Through 2030
Table 34 : Global Market for Noninvasive Cancer Diagnostics in Diagnostic Centers, by Region, Through 2030
Table 35 : Global Market for Noninvasive Cancer Diagnostics in Government and Private Research Institutes, by Region, Through 2030
Table 36 : Global Market for Noninvasive Cancer Diagnostics in Pharmaceutical Companies, by Region, Through 2030
Table 37 : Global Market for Noninvasive Cancer Diagnostics in Contract Research Organizations, by Region, Through 2030
Table 38 : Global Market for Noninvasive Cancer Diagnostics, by Region, Through 2030
Table 39 : North American Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 40 : North American Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 41 : North American Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 42 : North American Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
Table 43 : U.S. Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 44 : Canadian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 45 : Mexican Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 46 : European Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 47 : European Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 48 : European Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 49 : European Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
Table 50 : German Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 51 : U.K. Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 52 : French Market for Noninvasive Cancer Diagnostics, by Technology Type,Through 2030
Table 53 : Italian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 54 : Spanish Market for Noninvasive Cancer Diagnostics, by Technology Type,Through 2030
Table 55 : Rest of Europe Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 56 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 57 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 58 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 59 : Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Country, Through 2030
Table 60 : Chinese Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 61 : Indian Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 62 : Japanese Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 63 : South Korean Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 64 : Rest of Asia-Pacific Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 65 : South American Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 66 : South American Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 67 : South American Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 68 : MEA Market for Noninvasive Cancer Diagnostics, by Cancer Type, Through 2030
Table 69 : MEA Market for Noninvasive Cancer Diagnostics, by Technology Type, Through 2030
Table 70 : MEA Market for Noninvasive Cancer Diagnostics, by End User, Through 2030
Table 71 : Leading Manufacturers and Service Providers in the Global Noninvasive Cancer Diagnostics Market, 2024
Table 72 : Collaboration and Partnership in Global Noninvasive Cancer Diagnostics Market, 2023–2025
Table 73 : Acquisitions in Global Noninvasive Cancer Diagnostics Market, 2023–2025
Table 74 : Key Strategic Activities and Developments in Global Noninvasive Cancer Diagnostics Market, 2024–2025
Table 75 : Product Launches and Regulatory Approval in Global Noninvasive Cancer Diagnostics Market, 2023–2025
Table 76 : ESG Highlights, by Major Players, 2024
Table 77 : Abbreviations Used in This Report
Table 78 : Report Information Sources
Table 79 : Abbott: Company Snapshot
Table 80 : Abbott: Financial Performance, FY 2023 and 2024
Table 81 : Abbott: Product Portfolio
Table 82 : Abbott: News/Key Developments, 2023–2025
Table 83 : BD: Company Snapshot
Table 84 : BD: Financial Performance, FY 2024 and 2025
Table 85 : BD: Product Portfolio
Table 86 : BD: News/Key Developments, 2023–2025
Table 87 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 88 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 89 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 90 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024–2025
Table 91 : Exact Sciences Corp.: Company Snapshot
Table 92 : Exact Sciences Corp.: Financial Performance, FY 2023 and 2024
Table 93 : Exact Sciences Corp.: Product Portfolio
Table 94 : Exact Sciences Corp.: News/Key Developments, 2023–2025
Table 95 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 96 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 97 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 98 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023–2025
Table 99 : Guardant Health Inc.: Company Snapshot
Table 100 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Guardant Health Inc.: Product Portfolio
Table 102 : Guardant Health Inc.: News/Key Developments, 2024–2025
Table 103 : Hologic Inc.: Company Snapshot
Table 104 : Hologic Inc.: Financial Performance, FY 2024 and 2025
Table 105 : Hologic Inc.: Product Portfolio
Table 106 : Hologic Inc.: News/Key Developments, 2023–2025
Table 107 : Illumina Inc.: Company Snapshot
Table 108 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 109 : Illumina Inc.: Product Portfolio
Table 110 : Illumina Inc.: News/Key Developments, 2023–2025
Table 111 : Koninklijke Philips N.V.: Company Snapshot
Table 112 : Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024
Table 113 : Koninklijke Philips N.V.: Product Portfolio
Table 114 : Koninklijke Philips N.V.: News/Key Developments, 2024–2025
Table 115 : Labcorp: Company Snapshot
Table 116 : Labcorp: Financial Performance, FY 2023 and 2024
Table 117 : Labcorp: Product Portfolio
Table 118 : Labcorp: News/Key Developments, 2023–2025
Table 119 : Leica Biosystems Nussloch GmbH.: Company Snapshot
Table 120 : Leica Biosystems Nussloch GmbH.: Product Portfolio
Table 121 : Leica Biosystems Nussloch GmbH.: News/Key Developments, 2024–2025
Table 122 : QIAGEN: Company Snapshot
Table 123 : QIAGEN: Financial Performance, FY 2023 and 2024
Table 124 : QIAGEN: Product Portfolio
Table 125 : QIAGEN: News/Key Developments, 2024–2025
Table 126 : Revvity: Company Snapshot
Table 127 : Revvity: Financial Performance, FY 2023 and 2024
Table 128 : Revvity: Product Portfolio
Table 129 : Revvity: News/Key Developments, 2023–2025
Table 130 : Siemens Healthineers AG: Company Snapshot
Table 131 : Siemens Healthineers AG: Financial Performance, FY 2024 and 2025
Table 132 : Siemens Healthineers AG: Product Portfolio
Table 133 : Siemens Healthineers AG: Key Developments, 2024–2025
Table 134 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 135 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 136 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 137 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023–2025
Table 138 : List of a Few Emerging Startups/Market Disruptors

List of Figures

Summary Figure : Global Market Shares for Noninvasive Cancer Diagnostics, by Region, 2024
Figure 1 : Market Dynamics of Noninvasive Cancer Diagnostics
Figure 2 : Number of Patents for Noninvasive Cancer Diagnostics, by Leading Applicants, January 2025–October 2025
Figure 3 : Patent Shares for Noninvasive Cancer Diagnostics, by Jurisdiction, January 2025–October 2025
Figure 4 : Patent Shares for Noninvasive Cancer Diagnostics, by Type, January 2025–October 2025
Figure 5 : Global Market Shares for Noninvasive Cancer Diagnostics, by Cancer Type, 2024
Figure 6 : Global Market Shares for Noninvasive Cancer Diagnostics, by Technology Type, 2024
Figure 7 : Global Market Shares for Noninvasive Cancer Diagnostics, by End User, 2024
Figure 8 : Global Market Shares for Noninvasive Cancer Diagnostics, by Region, 2024
Figure 9 : Global Market Shares for Noninvasive Cancer Diagnostics, by Company, 2024
Figure 10 : Pillars of Sustainable Cancer Care
Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
Figure 13 : BD: Revenue Share, by Business Unit, FY 2025
Figure 14 : BD: Revenue Share, by Country/Region, FY 2025
Figure 15 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 16 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 17 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2024
Figure 18 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2024
Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 20 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 21 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024
Figure 22 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024
Figure 23 : Hologic Inc.: Revenue Share, by Business Unit, FY 2025
Figure 24 : Hologic Inc.: Revenue Share, by Country/Region, FY 2025
Figure 25 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 26 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 27 : Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024
Figure 28 : Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2024
Figure 29 : Labcorp: Revenue Share, by Business Unit, FY 2024
Figure 30 : Labcorp: Revenue Share, by Country/Region, FY 2024
Figure 31 : QIAGEN: Revenue Share, by Business Unit, FY 2024
Figure 32 : QIAGEN: Revenue Share, by Country/Region, FY 2024
Figure 33 : Revvity: Revenue Share, by Business Unit, FY 2024
Figure 34 : Revvity: Revenue Share, by Country/Region, FY 2024
Figure 35 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2025
Figure 36 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2025
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024